Currently out of the existing stock ratings of Brendan Smith, 30 are a BUY (66.67%), 15 are a HOLD (33.33%).

Brendan Smith

Work Performance Price Targets & Ratings Chart

Analyst Brendan Smith, currently employed at TD COWEN, carries an average stock price target met ratio of 66.03% that have a potential upside of 16.66% achieved within 74 days.

Brendan Smith’s has documented 91 price targets and ratings displayed on 13 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on TWST, Twist Bioscience Corp.

Wall Street Analyst Brendan Smith

Analyst best performing recommendations are on SLP (SIMULATIONS PLUS).
The best stock recommendation documented was for NVAX (NOVAVAX) at 8/4/2025. The price target of $8 was fulfilled within 3 days with a profit of $1.25 (18.52%) receiving and performance score of 61.73.

Average potential price target upside

AZTA Azenta CDXS Codexis CTKB Cytek Biosciences DNA Ginkgo Bioworks Holdings EVO Evotec SE ADR HALO Halozyme Therapeutics NVAX Novavax OABI OmniAb SLP Simulations Plus TKNO Alpha Teknova TWST Twist Bioscience Corp WST West Pharmaceutical Services CERT Certara

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 04-Feb-2026

$52

$6.35 (13.91%)

$30

Buy Since 07-May-2021

$37

$-8.65 (-18.95%)

$37

2 months ago
(14-Sep-2026)

12/31 (38.71%)

$4.96 (15.48%)

171

Buy Since 05-Feb-2026

$35

$-10.65 (-23.33%)

$35

3 months 8 days ago
(06-Aug-2026)

12/14 (85.71%)

$4.26 (13.86%)

106

Hold Since 27-Feb-2025

$30

$-15.65 (-34.28%)

$39

9 months 10 days ago
(04-Feb-2026)

3/4 (75%)

$1.51 (5.30%)

20

Buy Since 25-Nov-2025

$45

$-0.65 (-1.42%)

$35

11 months 20 days ago
(25-Nov-2025)

2/2 (100%)

$6.9 (18.11%)

232

Show more analysts

Please expand the browser size to see the chart

Which stock is Brendan Smith most bullish on?

Potential upside of $83.58 has been obtained for WST (WEST PHARMACEUTICAL SERVICES)

Which stock is Brendan Smith most reserved on?

Potential downside of -$0.61 has been obtained for DNA (GINKGO BIOWORKS HOLDINGS)

What Year was the first public recommendation made by Brendan Smith?

On 2023
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?